亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years

医学 骨量减少 观察研究 随机对照试验 股骨颈 物理疗法 骨质疏松症 儿科 内科学 骨矿物
作者
Ian R. Reid,Anne Horne,Borislav Mihov,Usha Bava,Angela Stewart,Gregory D. Gamble
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:12 (4): 247-256 被引量:17
标识
DOI:10.1016/s2213-8587(24)00003-2
摘要

Background We previously identified that zoledronate administered at 18-month intervals reduced fragility fractures by a third in a 6-year trial of women older than 65 years with osteopenia. This extension aims to identify the persistence of these effects. Methods Of the 2000 ambulant, community dwelling, postmenopausal women older than 65 years recruited in Auckland, New Zealand, with T-scores at the total hip or femoral neck in the range –1·0 to –2·5, we invited participants who received four doses of intravenous zoledronate, completed follow-up to year 6 of the core trial, did not have metabolic bone disease (other than osteoporosis), and were not using bone-active drugs into this 4-year observational study extension, during which further treatment was at the discretion of their own doctors. Participants were asked to notify study staff of any new fractures and were telephoned at 7·5 years and 9·0 years to update their health status. Participants were then invited to an onsite visit at 10·0 years. Fractures and other health events were documented at each contact and analysed in all women who entered the extension, and bone mineral density (BMD; analysed in participants without notable use of bone-active medications who attended an onsite visit at 10 years) and turnover markers (measured from fasting morning blood in a random subset of 50 participants) were measured at year 10. Findings Of the 1000 women randomly assigned to receive zoledronate in the core trial, 796 participants were eligible for the extension, of whom 762 (96%) entered the extension between Sept 24, 2015, and Dec 13, 2017. Mean follow-up duration was 4·24 years (SD 0·57, range 0·61–6·55; final follow-up on May 25, 2022). 727 (91%) of participants were assessed at 10 years. 25 women died during the extension, six withdrew for medical reasons, and four were lost to follow-up. 92 women suffered 114 non-vertebral fractures during the extension. Non-vertebral fracture rates increased from a nadir of 15 fractures per 1000 woman-years (95% CI 10–21) in the last 2 years of the core trial to 24 fractures (17–33) in years 6–8 and 42 fractures (32–53) in years 8–10, similar to that in the placebo group in the last 2 years of the core trial. Total hip BMD (relative risk per 0·1 g/cm2 0·73, 95% CI 0·57–0·93; p=0·011) and a previous history of non-vertebral fracture (1·74, 1·12–2·69; p=0·013) at year 6 predicted incident fractures but change in total hip BMD did not. Total hip BMD decreased from 4·2% above study baseline to 0·8% above baseline (p<0·0001) during the extension. Turnover markers were not useful for predicting BMD loss in individuals. Osteonecrosis of the jaw or atypical femoral fractures did not occur in any participants. Interpretation The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter. Funding Health Research Council of New Zealand.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
cc对应助文件撤销了驳回
5秒前
6秒前
停騮_ 完成签到,获得积分10
6秒前
搜集达人的应助被锅包肉采纳,获得10
7秒前
危机的奄完成签到,获得积分10
7秒前
成就书雪完成签到,获得积分0
8秒前
10秒前
哇二木耶完成签到,获得积分10
17秒前
18秒前
hogjluo完成签到,获得积分10
20秒前
追寻书本完成签到,获得积分10
21秒前
22秒前
锅包肉发布了新的文献求助10
25秒前
chen01hang的应助被EShiroYuki采纳,获得120
25秒前
星空完成签到 ,获得积分20
26秒前
27秒前
27秒前
FashionBoy的应助被cc采纳,获得10
28秒前
33秒前
李糯的饺子完成签到,获得积分10
34秒前
40秒前
VT完成签到,获得积分10
48秒前
顾矜的应助被锅包肉采纳,获得10
53秒前
华无剑的应助被VT采纳,获得10
54秒前
健康的兰完成签到,获得积分10
54秒前
所所的应助被Culto采纳,获得10
55秒前
1分钟前
一般般发布了新的文献求助10
1分钟前
1分钟前
lzy发布了新的文献求助10
1分钟前
积极的一江完成签到,获得积分10
1分钟前
1分钟前
1分钟前
lzy完成签到,获得积分20
1分钟前
1分钟前
orixero的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
null的应助被科研通管家采纳,获得30
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165954
求助须知:如何正确求助?哪些是违规求助? 9559332
关于积分的说明 21749951
捐赠科研通 7756726
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473657